C

Cyclacel Pharmaceuticals

D
CYCC
USD
-0.0341
(-7.75%)
Market Closed
13,530.00
Volume
-3.72
EPS
-
Div Yield
-0.026512
P/E
801,329.40
Market Cap
Today
-4.8523%
1 Week
-37.070%
1 Month
-56.214%
6 Months
-80.763%
12 Months
-95.442%
Year To Date
-84.854%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
C
CLRB
0.045
(2.1739%)
USD
D
DCTH
0
(0%)
USD
P
PTN
-0.005
(-0.4255%)
USD
A
ADMP
(%)
USD
C
CTIC
0.11
(2.5404%)
USD
A
AVXL
-0.2
(-2.551%)
USD
I
INFI
-0.0461
(-55.5422%)
USD
S
SLS
0.01
(0.8696%)
USD

Title:
Cyclacel Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Do you need help or have a question?
Contact Us